Expert Available To Discuss CDC Report Showing Poison Deaths Surpass Motor Vehicle Traffic Death Rates Among Adults 34 To 56 Adults between the ages of 34 and 56 are at a greater risk of dying from poisonings than from motor vehicle accidents, according to a new report from the CDC. The CDC's Morbidity and Mortality Weekly Report, released on Friday, states that poisoning death rates were higher than motor vehicle traffic death rates among adults aged 34 to 56 years between 2005 and 2006.
Source: www.medicalnewstoday.comSurvey: Illinois Seniors Delay Buying Prescription Drugs Some seniors in Illinois are delaying buying
prescription drugs because of the cost, according to the AARP. United Press International reports: "Twenty-one percent of AARP members surveyed in Illinois report not filling or delaying filling prescriptions due to cost, a survey indicated.
Source: www.medicalnewstoday.comLeading European Contract Research Organization Selects OmniComm To Provide EClinical Solutions For Important Phase III Study OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced that it has been selected by a leading European based Contract Research Organization (CRO) to provide eClinical solutions for a pivotal Phase III study in rheumatoid arthritis (RA).
Source: www.medicalnewstoday.comTAU Grows New Blood Vessels To Combat Heart Disease Although open-heart surgery is a frequent treatment for heart disease, it remains extremely dangerous. Now groundbreaking research from Dr. Britta Hardy of Tel Aviv University's Sackler School of Medicine has shown the potential for an injected protein to regrow blood vessels in the human heart - eliminating the need for risky surgery altogether.
Source: www.medicalnewstoday.comLancet Publishes 48 Week Phase III Data For 'Isentress'® (Raltegravir) In Previously Untreated (Treatment-Naïve) HIV-Infected Patients The online edition of The Lancet has published results from a forty-eight week Phase III study of previously untreated (treatment-naïve) HIV-infected patients which showed that 'Isentress'® (raltegravir), Merck Sharp & Dohme Limited's (MSD) first-in-class integrase inhibitor, was found to be as effective as efavirenz at suppressing viral load to undetectable levels (less than 50 copies/mL) when used in combination therapy.
Source: www.medicalnewstoday.com
# posted by Network @ 1:41 AM
